CN1934089A - 1,5-二苯基吡唑甲酸衍生物的制备方法 - Google Patents
1,5-二苯基吡唑甲酸衍生物的制备方法 Download PDFInfo
- Publication number
- CN1934089A CN1934089A CNA2005800076423A CN200580007642A CN1934089A CN 1934089 A CN1934089 A CN 1934089A CN A2005800076423 A CNA2005800076423 A CN A2005800076423A CN 200580007642 A CN200580007642 A CN 200580007642A CN 1934089 A CN1934089 A CN 1934089A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- following formula
- react
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
Abstract
本发明涉及式(I)化合物的制备方法:式中:W代表-COOR基团或-CN基;R1代表氢或卤素原子或(C1-C4)烷基;R2、R3、R4、R5、R6、R7每个彼此独自地代表氢或卤素原子或(C1-C4)烷基、(C1-C4)烷氧基或三氟甲基;R代表(C1-C4)烷基或苄基。
Description
本发明的目的是1,5-二苯基吡唑-3-甲酸衍生物的新制备方法。
人们已描述过1,5-二苯基-4-甲基吡唑-3-甲酸酯,具体地在欧洲专利EP 576 357和US 5 624 941中描述过这些酯。这些酯是制备1,5-二苯基-4-甲基吡唑-3-甲酸衍生物的有用中间体,它们是大麻素CB1受体的拮抗剂。
更特别地,在欧洲专利EP 656 354中描述的5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酸乙酯,是制备N-哌啶子基-5-(4-氯苯基)-1-(2,4二氯苯基)-4-甲基吡唑-3-甲酰胺的有用中间体,其国际通用名称是rimonabant。
本发明的目的是下式化合物的制备方法:
式中:
-W代表-COOR基团或-CN基;
-R1代表氢或卤素原子或(C1-C4)烷基;
-R2、R3、R4、R5、R6、R7每个彼此独自地代表氢或卤素原子或(C1-C4)烷基、(C1-C4)烷氧基或三氟甲基;
-R代表(C1-C4)烷基或苄基;
其特征在于在溶剂中,在碱性介质中的催化剂存在下,让下式苯基硼酸衍生物:
式中R5、R6和R7如式(I)中所定义,与下式化合物进行反应:
式中:
-W、R1、R2、R3、R4如式(I)中所定义;
-Y代表(C1-C4)烷基、(C1-C4)全氟烷基、未被取代或被甲基、氯或硝基取代的苯基。
特别地,本发明的目的是下式化合物的制备方法:
式中:
-R1、R2、R3、R4、R5、R6、R7和R如式(I)化合物所定义;
其特征在于在溶剂中,在碱性介质中的催化剂存在下,让如前面定义的式(II)苯基硼酸衍生物与下式化合物进行反应:
式中:
-Y、R、R1、R2、R3和R4如前面所定义。
还特别地,本发明的目的是下式化合物的制备方法:
式中:
-R1、R2、R3、R4、R5、R6和R7如式(I)化合物所定义;
其特征在于在溶剂中,在碱性介质中的催化剂存在下,让如前面定义的式(II)苯基硼酸衍生物与下式化合物进行反应:
式中:
-Y、R1、R2、R3和R4如前面所定义。
优选地,在例如甲苯的芳族溶剂中、或在例如四氢呋喃或二甲氧基乙烷的含醚溶剂中或在二氧杂环己烷中,在钯配合物,例如四(三苯基膦)钯的存在下和在碱性介质中,例如在碱金属碳酸盐存在下,例如在碳酸钠或碳酸钾存在下,进行式(II)化合物与式(III)、(IIIA)或(IIIB)化合物的反应。
根据一个优选实施方式,在双相介质中,在四(三苯基膦)钯的存在下进行该反应,碱性介质是由碳酸钠水溶液组成的。
根据制备式(I)化合物的优选方法,让式(II)苯基硼酸衍生物与式(III)化合物进行反应,式中Y代表CF3基团,即下式化合物:
还根据制备式(IA)化合物的优选方法,让式(II)苯基硼酸衍生物与式(IIIA)化合物进行反应,其中Y代表CF3,即下式化合物:
还根据制备式(IB)化合物的优选方法,让式(II)苯基硼酸衍生物与式(IIIB)化合物进行反应,其中Y代表CF3,即下式化合物:
更优选地,让4-氯苯基硼酸与下式化合物进行反应:
更优选地,让4-氯苯基硼酸与下式化合物进行反应:
还优选地,让4-氯苯基硼酸与下式化合物进行反应:
最后,更优选地,让4-溴苯基硼酸与下式化合物进行反应:
由下式吡唑酮衍生物得到式(III)化合物:
特别地,由下式吡唑酮衍生物得到式(IIIA)化合物:
特别地,由下式吡唑酮衍生物也得到式(IIIB)化合物:
为了制备式(III)、(IIIA)或(IIIB)化合物,让式(YSO2)2O酸酐或式YSO2Cl氯化物与式(IV)、(IVA)或(IVB)化合物进行反应;在碱,优选地叔胺存在下进行这个反应。
特别地,下式化合物:
是在例如叔胺的碱存在下,在例如二氯甲烷的溶剂中,由三氟甲基磺酸酐与下式吡唑酮衍生物反应得到的:
还特别地,下式化合物:
是在例如叔胺的碱存在下,在例如二氯甲烷的溶剂中,由三氟甲基磺酸酐与下式吡唑酮衍生物反应得到的:
最后,特别地,下式化合物:
是在例如叔胺的碱存在下,在例如二氯甲烷的溶剂中,由三氟甲基磺酸酐与下式吡唑酮衍生物反应得到的:
优选地,在二氯甲烷中,在温度-5℃至+5℃下,通过等摩尔的三氟甲基磺酸酐和三乙胺化合物的作用,得到式(III)、(IIIA)或(IIIB)化合物,其中Y代表CF3。
下式化合物:
是通过下式肼衍生物:
其中R2、R3、R4如式(I)所定义,与下式衍生物的反应得到的:
其中R、R1和W如上述式(I)所定义。
特别地,下式化合物:
是通过式(V)肼衍生物与下式衍生物的反应得到的:
还特别地,下式化合物:
是通过式(V)肼衍生物与下式衍生物的反应得到的:
优选地,在溶剂中,在酸性介质中,例如在乙酸中;或在有盐酸、乙酸或三氟乙酸的甲苯中,使用式(V)肼盐酸盐。
式(VI)、(VIA)或(VIB)3-氧代琥珀酸酯衍生物是已知的,或可采用已知的方法制备得到,例如烯醇酯与草酸酯的Claisen缩合反应。
式(IV)化合物能以两种互变异构体形态存在:
根据另一方面,本发明的目的是下式化合物:
式中:
-W代表-COOR基团或CN基;
-Y代表(C1-C4)烷基、(C1-C4)全氟烷基、未被取代或被甲基、氯或硝基取代的苯基;
-R1代表氢或卤素原子或(C1-C4)烷基;
-R2、R3、R4每个彼此独自地代表氢或卤素原子或(C1-C4)烷基、(C1-C4)烷氧基、三氟甲基;
-R代表(C1-C4)烷基或苄基。
优选地,本发明的目的是下式化合物:
式中:
-Y、R、R1、R2、R3和R4如前面所定义。
优选地,本发明的目的是下式化合物:
式中:
-Y、R1、R2、R3和R4如前面所定义。
更优选地,本发明的目的是下式化合物:
还优选地,本发明的目的是下式化合物:
还优选地,本发明的目的是下式化合物:
还优选地,本发明的目的是下式化合物:
下述实施例是非限制性的,它说明本发明的实施方式。
以所谓的电喷雾(ES)电离方式测量质谱。
NMR观察信号表示如下:s:单峰;se:展宽单峰;d:双峰;d.d:分裂双峰;t:三重峰;td:分裂三重峰;q:四重峰;m:未分辨峰;mt:多重峰。
实施例1
制备5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酸乙酯。
A)1-(2,4-二氯苯基)-4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-甲酸乙酯。
在氮气下,把12.6g 2,4-二氯苯基肼盐酸盐加到100ml甲苯中;搅拌后,添加10g 2-甲基-3-氧代琥珀酸二乙酯,然后加热与在55℃添加5ml TFA。在搅拌下让其溶剂回流4.5小时。再返回到TA,再加热到75℃,用30ml水使该反应介质水解。倾析,分离含水相,然后蒸发有机相除去残留的TFA。该有机相用10ml甲苯回收,期望产物进行结晶,m=10.2g。
ES-:[M-H]-=313.0
NMR(DMSO-d6 1H,在300MHz):1.26ppm:t:3H;2.11ppm:s:3H;4.23ppm:q:2H;7.57ppm:m:2H;7.87ppm:se:1H;11.04ppm:se:1H.
B)1-(2,4-二氯苯基)-4-甲基-5-(((三氟甲基)磺酰基)氧基)-1H-吡唑-3-甲酸乙酯。
在氮气下,将5g在前面步骤得到的吡唑酮悬浮于25ml DCM中,并在搅拌下冷却到0℃。添加2.4ml TEA,再添加3ml三氟甲基磺酸酐,在0℃下保持搅拌15分钟。该反应介质用20ml DCM进行水解。倾析该反应介质,然后有机相用20ml水洗涤。分离含水相。蒸发有机相,得到的油进行硅胶柱色谱纯化,用戊烷/AcOEt混合物(90/10;v/v)洗脱。含有期望化合物的这些馏分合并并蒸发至干。得到6.77g期望化合物。
ES+:[M+Na]+=468.8
NMR(DMSO-d61H,在300MHz):1.31ppm:t:3H;2.27ppm:s:3H;4.34ppm:q:2H;7.72ppm:dd:1H;7.79ppm:d:1H;8.04ppm:d:1H.
C)5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酸乙酯。
在氮气下,让2.55g在前面步骤得到的三氟甲基磺酸吡唑、1.08g 4-氯苯基硼酸和67mg四(三苯基膦)钯混合在一起;添加25ml甲苯和7.1ml 2M碳酸钠水溶液。该反应介质在65℃搅拌6小时。倾析反应介质,分离含水相,然后用10ml水洗涤有机相。倾析后,蒸发有机相。得到的产物进行硅胶柱色谱纯化,用环己烷/AcOEt混合物(85/15;v/v)洗脱。得到1.890g期望化合物。
NMR(DMSO-d61H,在300MHz):1.31ppm:t:3H;2.23ppm:s:3H;4.32ppm:q:2H;7.24ppm:d:2H;7.46ppm:d:2H;7.57ppm:dd:1H;7.73ppm:d:1H;7.77:d:1H.
Claims (17)
2.根据权利要求1所述的下式化合物制备方法:
式中:
-R1、R2、R3、R4、R5、R6、R7和R如权利要求1式(I)化合物所定义;
其特征在于让如权利要求1定义的式(II)苯基硼酸衍生物与下式化合物进行反应:
式中:
-Y、R1、R2、R3和R4如权利要求1所定义。
4.根据权利要求1所述的方法,其特征在于让如权利要求1所限定的式(II)苯基硼酸衍生物与下式化合物进行反应:
式中:
-W、R1、R2、R3、R4如权利要求1所定义。
13.根据权利要求11所述的下式化合物:
式中:
-Y、R1、R2、R3和R4如权利要求11中所定义。
17.根据权利要求13所述的下式化合物:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0405057 | 2004-05-10 | ||
FR0405057A FR2869905B1 (fr) | 2004-05-10 | 2004-05-10 | Procede de preparation d'ester de l'acide 1,5-diphenylpyrazole carboxylique. |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1934089A true CN1934089A (zh) | 2007-03-21 |
Family
ID=34945575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800076423A Pending CN1934089A (zh) | 2004-05-10 | 2005-05-10 | 1,5-二苯基吡唑甲酸衍生物的制备方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7358371B2 (zh) |
EP (1) | EP1753726B1 (zh) |
JP (1) | JP4855392B2 (zh) |
KR (1) | KR20070007797A (zh) |
CN (1) | CN1934089A (zh) |
AR (1) | AR048892A1 (zh) |
AT (1) | ATE454374T1 (zh) |
AU (1) | AU2005247642A1 (zh) |
BR (1) | BRPI0511053A (zh) |
CA (1) | CA2557284A1 (zh) |
DE (1) | DE602005018770D1 (zh) |
FR (1) | FR2869905B1 (zh) |
IL (1) | IL177701A0 (zh) |
NO (1) | NO20064058L (zh) |
RU (1) | RU2326116C1 (zh) |
TW (1) | TW200615263A (zh) |
UY (1) | UY28887A1 (zh) |
WO (1) | WO2005115989A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008101860A1 (en) * | 2007-02-20 | 2008-08-28 | Sandoz Ag | Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2020939C3 (de) * | 1970-04-29 | 1978-11-02 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches Aufzeichnungsmaterial |
JPS5420856B2 (zh) * | 1971-11-04 | 1979-07-26 | ||
JPS5139225B2 (zh) * | 1973-09-18 | 1976-10-26 | ||
JPS6037145B2 (ja) * | 1982-11-16 | 1985-08-24 | 日本化薬株式会社 | モノアゾ化合物及びそれを用いる疎水性繊維の染色法 |
JPS59230064A (ja) * | 1983-06-13 | 1984-12-24 | Mitsubishi Chem Ind Ltd | モノアゾ染料混合体 |
DE3634393A1 (de) * | 1986-10-09 | 1988-04-14 | Basf Ag | Solventfarbstoffe mit carbonsaeurefunktionen |
US5079370A (en) * | 1989-03-02 | 1992-01-07 | Rhone-Poulenc Ag Company | 1-arylpyrazoles |
WO1992013451A1 (en) * | 1991-02-11 | 1992-08-20 | Schering Agrochemicals Limited | Imidazole pesticides |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
JP2855036B2 (ja) * | 1992-10-20 | 1999-02-10 | 富士写真フイルム株式会社 | 多色感熱記録材料及びそれを用いた画像記録方法 |
US5447831A (en) * | 1993-10-19 | 1995-09-05 | Eastman Kodak Company | Photographic element employing hue correction couplers |
JPH0961163A (ja) * | 1995-08-25 | 1997-03-07 | Asia Kosoku Kk | 航空写真撮影方法 |
JPH09126671A (ja) * | 1995-11-01 | 1997-05-16 | Kitashiba Denki Kk | ヒートパイプおよびヒートパイプの埋設方法 |
JPH1083041A (ja) * | 1996-09-06 | 1998-03-31 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
PL364874A1 (en) * | 1999-12-02 | 2004-12-27 | Bayer Cropscience S.A. | Control of arthropods in animals |
US6410533B1 (en) * | 2000-02-10 | 2002-06-25 | Genzyme Corporation | Antibacterial compounds |
-
2004
- 2004-05-10 FR FR0405057A patent/FR2869905B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-06 UY UY28887A patent/UY28887A1/es not_active Application Discontinuation
- 2005-05-09 AR ARP050101866A patent/AR048892A1/es active IP Right Grant
- 2005-05-09 TW TW094114828A patent/TW200615263A/zh unknown
- 2005-05-10 RU RU2006133644/04A patent/RU2326116C1/ru active
- 2005-05-10 DE DE602005018770T patent/DE602005018770D1/de active Active
- 2005-05-10 AT AT05770985T patent/ATE454374T1/de not_active IP Right Cessation
- 2005-05-10 WO PCT/FR2005/001155 patent/WO2005115989A1/fr not_active Application Discontinuation
- 2005-05-10 EP EP05770985A patent/EP1753726B1/fr active Active
- 2005-05-10 KR KR1020067018384A patent/KR20070007797A/ko not_active Application Discontinuation
- 2005-05-10 CA CA002557284A patent/CA2557284A1/fr not_active Abandoned
- 2005-05-10 AU AU2005247642A patent/AU2005247642A1/en not_active Abandoned
- 2005-05-10 BR BRPI0511053-0A patent/BRPI0511053A/pt not_active IP Right Cessation
- 2005-05-10 CN CNA2005800076423A patent/CN1934089A/zh active Pending
- 2005-05-10 JP JP2007512278A patent/JP4855392B2/ja not_active Expired - Fee Related
-
2006
- 2006-08-24 IL IL177701A patent/IL177701A0/en unknown
- 2006-09-08 NO NO20064058A patent/NO20064058L/no not_active Application Discontinuation
- 2006-10-10 US US11/548,008 patent/US7358371B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20070099978A1 (en) | 2007-05-03 |
CA2557284A1 (fr) | 2005-12-08 |
NO20064058L (no) | 2006-09-08 |
TW200615263A (en) | 2006-05-16 |
FR2869905A1 (fr) | 2005-11-11 |
IL177701A0 (en) | 2006-12-31 |
RU2326116C1 (ru) | 2008-06-10 |
BRPI0511053A (pt) | 2007-11-27 |
RU2006133644A (ru) | 2008-03-27 |
WO2005115989A1 (fr) | 2005-12-08 |
UY28887A1 (es) | 2005-12-30 |
EP1753726A1 (fr) | 2007-02-21 |
AU2005247642A1 (en) | 2005-12-08 |
KR20070007797A (ko) | 2007-01-16 |
DE602005018770D1 (de) | 2010-02-25 |
EP1753726B1 (fr) | 2010-01-06 |
JP4855392B2 (ja) | 2012-01-18 |
AR048892A1 (es) | 2006-06-07 |
FR2869905B1 (fr) | 2008-09-05 |
US7358371B2 (en) | 2008-04-15 |
JP2007536357A (ja) | 2007-12-13 |
ATE454374T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1290832C (zh) | 作为高选择性的环加氧酶-2抑制剂的1h-吲哚衍生物 | |
CN100338029C (zh) | 2-卤代酰基-3-氨基-丙烯酸-衍生物的制备方法 | |
CN1146544C (zh) | 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 | |
CN1069098C (zh) | 新的咪唑衍生物及其制备方法 | |
CN1871204A (zh) | 制备2-二卤代酰基-3-氨基丙烯酸酯以及3-二卤代甲基吡唑-4-羧酸酯的方法 | |
CN1913885A (zh) | 具有cb1-拮抗活性的1,3,5-三取代的4,5-二氢-1h-吡唑衍生物 | |
CN1869036A (zh) | 7-取代-3-氯吡咯并[3,4-b]吡啶化合物 | |
CN1419546A (zh) | 具有cb1-拮抗活性的4,5-二氢-1h-吡唑衍生物 | |
CN1944406A (zh) | 吲哚类杂环化合物和中间体、以及合成方法 | |
CN1216049C (zh) | 西酞普兰的制备方法 | |
CN1117736C (zh) | 2-(3-吡唑基氧基亚甲基)硝基苯的制备方法 | |
CN1052979C (zh) | 恩丹西酮的制备方法 | |
CN1279683A (zh) | 8-甲氧基-喹诺酮羧酸类的制备方法 | |
CN1665773A (zh) | N-单取代β-氨基醇的制备方法 | |
CN1037147A (zh) | N-环丙基苯胺及其在制备1-环丙基喹诺酮羧酸和其衍生物中的应用 | |
CN1330072A (zh) | 用于制备1-(卤代芳基)杂环农药化合物的中间体 | |
CN1934089A (zh) | 1,5-二苯基吡唑甲酸衍生物的制备方法 | |
CN1847218A (zh) | 羟基萘二甲酸酰肼及其衍生物和制备它们的方法 | |
CN1688587A (zh) | 噻吩并吡咯衍生物的制备方法和中间体 | |
CN1174961C (zh) | 制备三唑啉酮所用的中间体及其制备方法 | |
CN1948310A (zh) | 3-位取代中氮茚类化合物和高效合成方法 | |
CN1205204C (zh) | 3-羟甲基-苯并[b]噻吩衍生物及其制备方法 | |
CN1244532C (zh) | 制备中间体的方法 | |
CN1255404C (zh) | 制备取代的咪唑并吡啶化合物的方法 | |
CN101039903A (zh) | N-(1-二苯甲基-吖丁啶-3-基)-n-苯基-甲基磺酰胺衍生物的新制备方法与中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1103076 Country of ref document: HK |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20070321 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1103076 Country of ref document: HK |